Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).
Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).
Two weeks of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd (moderate certainty).
Two weeks of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd (low certainty).
Two weeks of AmBd + 5FC showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (low certainty).
Resistance testing showed no clear difference in mortality compared with no resistance testing (moderate certainty).
Resistance testing may leads to lower virological failure compared with no resistance testing (low certainty).
Resistance testing showed no clear difference in progression to AIDS compared with no resistance testing (moderate certainty).
Resistance testing showed no clear difference in adverse events compared with no resistance testing (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (low certainty).
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).